63 results about "Tryptophan Metabolism Pathway" patented technology

The invention relates to an oxadiazole derivative, a preparation method therefor and use of the oxadiazole derivative in medicines. Particularly, the invention relates to an oxadiazole derivative represented by a general formula (I) shown in the description, a preparation method therefor, a pharmaceutical composition containing the derivative and use of the pharmaceutical composition in preparation of drugs for preventing and/or treating diseases with IDO mediated pathological features of a tryptophan metabolism pathway, wherein the diseases comprise cancer, Alzheimer's disease, autoimmune disease, melancholia, anxiety neurosis, cataract, psychological barrier and acquired immunodeficiency syndrome. Each substituent of the general formula (I) is the same as defined in the specification.

The invention relates to a preparation method of tryptanthrin compound and a new application of tryptanthrin compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor, in particular to an application of tryptanthrin compound in preparing IDO inhibitor and in preparing medicine for preventing and/or treating diseases having pathological characteristics of tryptophan metabolic disturbance mediated by IDO. The structure of the tryptanthrin compound is shown in formula A in the description, wherein R1 and R2 are respectively and independently selected from hydrogen, nitryl, C1 to C5 alkyl, halogen or piperazinyl. The tryptanthrin compound can be used as an IDO inhibitor with high activity and is used for treating diseases having pathological characteristics of tryptophan metabolic disturbance mediated by IDO such as tumor, cancer, Alzheimer disease, autoimmune disease, cataract, mental block, tristimania, anxiety neurosis, acquired immure deficiency syndrome (AIDS) and other serious diseases, and as a medicinal resource which is very difficult to get, the tryptanthrin compound has good potential on researching and developing new medicine.

The invention relates to novel application of berberine and derivatives thereof in preparation of medicines, in particular to application of berberine and derivatives thereof in preparation of indole amine 2, 3-dioxygenase IDO inhibitor, belonging to the medicine field. According to IDO inhibition activity detection, reversible inhibition judgment, inhibitor type judgment, Ki value determination and median effective inhibition concentration IC50 determination, the results show that berberine is reversible inhibitor and inhibition constant Ki is 8muM; and jatrorrhizine hydrochloride and palmatine hydrochloride are irreversible inhibitors, and the median effective inhibition concentrations IC50 thereof are respectively 123muM and 126muM. When the berberine and the derivatives thereof disclosed in the invention are used as IDO inhibitors, the application prospect is wide and the IDO inhibitors can be used for treating serious diseases such as cancers, AIDS, Alzheimer diseases, tristimania, cataract and the like with pathological feature of IDO-mediated tryptophan metabolism.

The invention relates to a novel indoleamine-2,3-dioxygenase (IDO) inhibitor, as well as a preparation method and an application thereof. The inhibitor is compounds of a formula I or pharmaceutically-acceptable salt, solvate, polymorph, enantiomer or racemic mixture thereof, wherein R1 or R2 is independently selected from H, C1-C5 alkyl, halogen and a substituent of a formula II and either of R1 and R2 is the substituent of the formula II; R3 is an aryl group; and n is equal to 0, 1, 2 or 3. Compared with the know IDO inhibitors, the novel IDO inhibitor has significant inhibitory effect on IDO and can be used for treatment of diseases having IDO-mediated tryptophan metabolic pathway pathological features, such as tumors, cancers, Alzheimer's disease, autoimmune diseases, cataract, psychological disorders, depression and/or anxiety. The preparation method of the novel IDO inhibitor has the advantages of being convenient in operation, having mild reaction conditions and reducing solvent consumption and pollution, thereby facilitating industrial production.

The invention relates to an oxadiazole derivative, a preparing method of the oxadiazole derivative and application of the oxadiazole derivative to medicines, in particular to an oxadiazole derivative shown in the general formula (1), a preparing method of the oxadiazole derivative, a medicine composition comprising the derivative and application of the oxadiazole derivative to treatment of diseases with the tryptophan metabolic pathway pathological feature mediated by IDO. The diseases include the cancer, the alzheimer disease, the autoimmune disease, the depression, the anxiety disorder, the cataract, the psychological disorder and the AIDS. Definition of substituent groups in the general formula (1) is the same with the definition of the substituent groups in the specification.

The invention belongs to the medicinal field, and concretely relates to a use of a 8-nitrotryptanthrin compound as an IDO inhibitor. The 8-nitrotryptanthrin compound is a reversible IDO inhibitor, has an inhibition constant Ki of 0.054muM, has in-vitro and cell-based median effective inhibition concentrations IC50 of 0.103muM and 1.80*10<-5>muM respectively, and has an inhibition effectiveness obviously better than a present inhibitor 1-methyltryptophan (Ki of 34muM and IC50 of 340muM). 8-nitrotryptanthrin disclosed in the invention can effectively lower the abnormally-increasing IDO activity in a tumor animal model as the IDO inhibitor, and also has tumor treatment effects comprising tumor growth delaying, tumor volume reduction and in-vitro tumor cell killing. 8-nitrotryptanthrin disclosed in the invention has a wide application prospect, and can be used for treating serious diseases having the IDO mediated tryptophan metabolism approach pathology characteristics, such as cancers, the Alzheimer disease, tristimania, cataract and the like as the IDO inhibitor.

The invention belongs to the technical field of new drug synthesis, and in particular relates to an IDO inhibitor containing (E)-4-(beta-bromovinyl)phenoxy acyl structure, as well as a preparation method thereof. The preparation method comprises the following steps: solvent benzene, (E)-4-(beta-bromovinyl) phenol, carboxylic acid and p-dimethylaminopyridine are added to a flask respectively and magnetically stirred for 5 to 20 minutes at room temperature; then N, N'-dicyclohexylcarbodiimide is added and reacts for 2 to 24 hours at room temperature; after the reaction is completed, the solvent benzene is steamed off after decompression; residue is subjected to column chromatography separation and purification by taking ethyl acetate/petroleum ether as leacheate, and then a needed product can be obtained, wherein the molar ratio of the solvent benzene to the (E)-4-(beta-bromovinyl) phenol is 50-200:1; the molar ratio of the carboxylic acid to the (E)-4-(beta-bromovinyl) phenol is 1-1.5:1; the molar ratio of the p-dimethylaminopyridine to the (E)-4-(beta-bromovinyl) phenol is 0.1-1.5:1; and the molar ratio of the N, N'-dicyclohexylcarbodiimide to the (E)-4-(beta-bromovinyl) phenol is 1-1.2:1. The method takes the (E)-4-(beta-bromovinyl) phenol as a synthesis building block and obtains a series of the novel IDO inhibitors containing the (E)-4-(beta-bromovinyl)phenoxy acyl structure through esterification reaction, and the IDO inhibitors can be used for treating the diseases with the pathological features of IDO mediated tryptophan metabolic pathway.

The invention relates to an oxadiazoles derivative, a preparation method and a medical application thereof, in particular to the oxadiazoles derivative of general formula 1, the preparation method, a drug composition containing the oxadiazoles derivative, and the application thereof in preparing medicines which can prevent and/or cure diseases with an IDO mediated tryptophan metabolic pathway histopathologic characteristic. The diseases comprise cancer, alzheimer disease, autoimmune disease, depression, anxiety disorder, cataract, psychologic obstacle and HIV disease. Each substituent of the general formula (1) is same with the definition in the description.

The invention belongs to the field of pharmaceutical chemistry and relates to a 1, 2, 3-triazole compound, comprising 4-(2-bromophenyl)-1H-1, 2, 3-triazole and 4-(2-chlorphenyl)-1H-1, 2, 3-triazole. The result of an inhibitory activity test of indoleamine 2, 3-dioxygenase indicates that the disclosed 1, 2, 3-triazole compound used as the indoleamine 2, 3-dioxygenase inhibitor has broad prospect of application and can be applied to the treatment of diseases with indoleamine 2, 3-dioxygenase-mediated tryptophan metabolic pathway pathological characteristics, including cancer, AIDS (Acquired Immure Deficiency Syndrome), Alzheimer disease, tristimania, cataract and other critical diseases.

The invention belongs to the technical field of medicines and in particular discloses a compound shown as a formula I or a formula II. Each symbol is defined as claims. The compound shown as the formula I or the formula II, provided by the invention, can be used as an IDO (Indoleamine-2,3-dioxygenase) regulator; the invention specifically discloses application of the compound to preparation of a medicine for treating IDO-mediated diseases with tryptophan metabolic pathway pathologic features. The formula I and the formula II are shown in the description.

The invention belongs to the technical fields of medicaments and intermediate synthesis, and in particular relates to vitamin K3 derivatives and a preparation method thereof. The 1,4-naphthoquinone derivatives are conveniently synthesized by using 2-bromine-1,4-naphthoquinone as raw materials through one-step reaction. The vitamin K3 derivatives synthesized by the method contain vitamin K3 structures and can be used as medicaments and important synthesized intermediates. The method for preparing the vitamin K3 derivatives has the characteristics of simple operation, mild condition, low cost, high yield, and the like, has wide application prospect, and is easy for industrialized production. An IDO inhibitor synthesized by the method and containing the vitamin K3 structure can be applied to the treatment of diseases with IDO-mediated tryptophan metabolic pathway pathologic features, wherein the diseases at least comprise tumor diseases, cancers, Alzheimer, autoimmune diseases, cataracts, mood disorders, depression, and anxiety disorder.

The invention relates to fused imidazole compounds, and a preparation method and application thereof. The structure of the compounds is shown in a general formula I, wherein the definitions of each group are as described in the specification. The compounds are capable of selectively inhibiting indoleamine 2,3-dioxygenase (IDO). The compounds provided by the invention can be used as IDO inhibitorsfor the treatment and/or prevention of diseases with the pathological characteristics of IDO mediated tryptophan metabolism pathways, such as cancer, eye diseases, autoimmune diseases, psychological disorders, depression, anxiety and other diseases.

The invention provides a compound as shown in a formula (I). The invention also relates to a pharmaceutical composition containing the compound of the formula (I) and application of the compound to preparation of an indoleamine-2,3-dioxygenase (IDO) inhibitor drug. The compound prepared by the method of the invention has an obvious inhibiting effect on IDO protease and is stable in metabolism in vivo. The compound or a pharmaceutical composition thereof provided by the invention can be used for preparing the IDO inhibitor drug, and can also be used for preparing medicines for preventing and/ortreating diseases with pathological characteristics of an IDO-mediated tryptophan metabolic pathway.

The invention relates to the field of pharmaceutical chemistry and particularly relates to an iodoleamine-2,3-dioxygenase 1 inhibitor (I), represented by a formula (I) shown in the description, with a nitrogen-containing benzoheterocyclic structure, wherein X, R, n and m are as defined in the description. Proven by pharmacodynamic tests, the compound disclosed by the invention can be used for treating diseases with IDO1 mediated pathological features of a tryptophan metabolism pathway such as malignant tumors, autoimmune diseases, Alzheimer's disease and schizophrenia.

The invention relates to the field of medicinal chemistry, in particular to an IDO1 (indoleamine-2,3-dioxygenase 1) inhibitor (I) of a phthalimide structure and a preparation method, wherein X and R are defined in the specification. A pharmacodynamic test shows that the compound can be used for treating diseases with the histopathologic characteristic of an IDO1-mediated tryptophan metabolism pathway, such as malignant tumors, autoimmune diseases, Alzheimer's disease and schizophrenia. (The formula is shown in the specification).

The invention relates to the technical field of indoleamine 2, 3-dioxygenase inhibitors, in particular to an indoleamine 2, 3-dioxygenase inhibitor with a tanshinone compound as the active substance.IDO inhibitory activity detection shows that the tanshinone compound of the structure or pharmaceutically acceptable salts thereof can have an inhibitory effect on IDO, and can obstruct and/or damagethe promotion effect of IDO in occurrence and development of diseases, thus providing good prospects for treatment of IDO mediated tryptophan metabolic pathway pathological feature diseases.

An N-alkyl tryptanthrin derivative, a preparation method for same, and an application thereof are provided. The structure of the derivative is as represented by formula I. The N-alkyl tryptanthrin derivative can serve as a highly active IDO inhibitor, for use in preparing a medicament for prevention and/or treatment of a disease having a pathological characteristic of an IDO-mediated tryptophan metabolic pathway.

The present invention relates to an imidazo isoindole derivative, a preparation method therefor and a medical use thereof. In particular, the present invention relates to the imidazo isoindole derivative as shown in the formula (I), a preparation method and pharmaceutical composition containing the derivative, and a use thereof for treating diseases with a pathological characteristic of the IDO-mediated tryptophan metabolic pathways. The diseases comprise cancers, Alzheimer's disease, autoimmune diseases, depression, anxiety disorders, cataracts, psychological disorders and AIDS, wherein the substituents in the formula (I) are the same as those defined in the specification.

The invention provides application of natural quassia alkaloids or pharmacologically acceptable salts of the natural quassia alkaloids serving as an indoleamine-2,3-dioxygenase (IDO) inhibitor. The quassia alkaloids or the pharmacologically acceptable salts of the quassia alkaloids serving as the IDO inhibitor can be used for preparing drugs, food, health products, food additives or nutritional supplements for preventing and/or curing pathological feature diseases caused by the fact that tryptophan metabolic pathways are mediated by IDO over-activation, and the diseases are selected from one or more of cancers, depression, Alzheimer disease and Parkinsonism.